Enterprise Value
0.00
Cash
605.5M
Avg Qtr Burn
N/A
Short % of Float
8.32%
Insider Ownership
0.32%
Institutional Own.
86.52%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Mirvetuximab Soravtansine (Folate receptor alpha (FRa)) Details Ovarian cancer, Cancer | Approved Quarterly sales | |
ELAHERE (Mirvetuximab Soravtansine) Details Cancer, Ovarian cancer | Approved Quarterly sales | |
Pivekimab Sunirine (IMGN632) (Anti-CD123 ADC) + Venclexta® + Vidaza® Details Cancer, Acute myeloid leukemia | Phase 2 Data readout | |
Pivekimab Sunirine (IMGN632) (Anti-CD123 ADC) Details Blastic plasmacytoid dendritic cell neoplasm | Phase 2 Data readout | |
Mirvetuximab Soravtansine (Folate receptor alpha (FRa)) Details Ovarian cancer, Cancer | Phase 2 Data readout | |
IMGN151 (anti-ADAM9 ADC) Details Cancer, Solid tumor/s, Endometrial cancer | Phase 1 Data readout | |
IMGC936 Details Solid tumor/s, Cancer, Triple-negative breast cancer | Phase 1 Data readout |